<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01249690</url>
  </required_header>
  <id_info>
    <org_study_id>SHCZH-2010-CT-001</org_study_id>
    <nct_id>NCT01249690</nct_id>
  </id_info>
  <brief_title>Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Union hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Hematology and Oncology Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Jishuitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the efficacy of PAD-regimen and TAD-regimen
      in newly diagnosed multiple myeloma(MM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma (MM) is a malignant tumor with abnormal proliferation of monoclonal plasma
      cells in bone marrow. Bone damage is one of the characteristic clinical manifestations.
      Myeloma plasma cells and bone marrow microenvironment are the targets of thalidomide and
      bortezomib. The regimens based on them as first-line treatments of MM have greatly improved
      efficacy and prolonged the survival of MM patients. But whether the regimens can prevent and
      treat bone complications of MM patients or improve the quality of life is not clear. By
      evaluating the efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and
      TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in MM and the effect of them on bone
      lesions, this study can provide evidence of evidence-based medicine for MM treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The overall response rate of PAD and TAD in patients with MM assessed by International Myeloma Working Group(IMWG) criteria</measure>
    <time_frame>every treatment cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The concentrations of bone metabolites</measure>
    <time_frame>every two cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chromosome examination by cytogenetic and interphase Fluorescence in situ hybridization(FISH) method</measure>
    <time_frame>at baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS) and progression-free survival(FPS)</measure>
    <time_frame>two and a half year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organisation for Research and Treatment of Cancer Quality Of life-Questionnaires-C30 (EORTC QLQ-C30)</measure>
    <time_frame>every two cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>PAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib,Pirarubicin,Dexamethasone</intervention_name>
    <description>Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.</description>
    <arm_group_label>PAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide,Pirarubicin,Dexamethasone</intervention_name>
    <description>Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.</description>
    <arm_group_label>TAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with symptomatic and measurable newly diagnosed Multiple Myeloma.

          -  Age &gt; 18 years, KPS ≥ 60, and life expectancy of at least 3 months.

          -  Subjects must meet all of the following criteria within 14 days before starting
             therapy:

        PLT≥50×109/L, Hb≥70 g/L, ANC≥0.75×109/L

          -  Subjects (or their legally acceptable representatives) must signed an informed consent
             document.

        Exclusion Criteria:

          -  Severe cardiovascular disease ; HIV infection, or positive HBsAg, or active hepatitis
             C; HBV-DNA&gt;104; hepatic functional parameter&gt;2.5 times the upper limit of
             institutional laboratory normal.

          -  Grade 2 or more severe peripheral neuropathy or neuropathic pain; Grade 2 or more
             severe impaired hepatic and kidney function.

          -  Patient has radiotherapy or major surgery within 30 days before enrollment.

          -  Patient has hypersensitivity to boron, mannitol or thalidomide.

          -  Pregnant or breastfeeding women, or subject unwilling to use a method for
             contraception during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Hou, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Changzheng Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shang Hai</city>
        <state>Shang Hai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hou</last_name>
      <email>houjian_czyy@sina.cn</email>
    </contact>
    <investigator>
      <last_name>Jian Hou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>November 29, 2010</last_update_submitted>
  <last_update_submitted_qc>November 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hou Jian/Director of department of hematology</name_title>
    <organization>Shanghai Changzheng Hospital, the Second Military Medical University</organization>
  </responsible_party>
  <keyword>Bortezomib,Thalidomide,bone metabolites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pirarubicin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

